Mallinckrodt to merge with Endo in a $6.7bn deal.

Mallinckrodt, an American-Irish domiciled manufacturer of specialty pharmaceuticals, agreed to merge with Endo, an American diversified pharmaceutical company, in a $6.7bn deal. "Our businesses are highly complementary, with durable, on-market products in our branded portfolios and extensive capabilities across the value chain in our generics businesses. This exciting combination will create a larger and more diversified entity with the scale and resources needed to unlock the full potential of both companies," Siggi Olafsson, Mallinckrodt President and CEO.